Trial Profile

A Phase I of ABI-010 (Nab-17-AAG) and ABI-007 (Abraxane) Administered Weekly in Patients With Advanced Non-Hematologic Malignancies.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NTB 010 (Primary) ; Paclitaxel (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Celgene Corporation

Most Recent Events

15 Jul 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
16 May 2011 Planned initiation date changed from 1 Feb 2009 to 1 Apr 2012 as reported by ClinicalTrials.gov.
16 May 2011 Planned End Date changed from 1 Apr 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com